Hepati ti s B is a viral infecti on that att acks the liver and can cause both acute and chronic  disease. 

Hepati ti s B is a major global health problem, a potenti ally life-threatening liver infecti on caused by the hepati ti s B virus. This infecti on cause chronic liver disease and puts people at high risk of death from cirrhosis of the liver and liver cancer. Worldwide, an esti mated two billion people have been infected with the hepati ti s B virus (HBV), and more than 360 million have chronic liver infecti ons.
A vaccine against hepati ti s B has been available since 1982. Hepati ti s B vaccine is 95% eff ecti ve in preventi ng HBV infecti on and its chronic consequences, and is the fi rst vaccine against a major human cancer.
Symptoms
Hepati ti s B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fati gue, nausea, vomiti ng and abdominal pain. People can take several months to a year to recover from the symptoms. HBV can also cause a chronic liver infecti on that can later develop into cirrhosis of the liver or liver cancer.
Who is most at risk for chronic disease?
The likelihood that an HBV infecti on will become chronic depends upon the age at which a person becomes infected, with young children who become infected with HBV being the most likely to develop chronic infecti ons. About 90% of infants infected during the fi rst year of life develop chronic infecti ons; 30% to 50% of children infected between one to four years of age develop chronic infecti ons. About 25% of adults who become chronically infected during childhood die from HBVHepatitis B related liver cancer or cirrhosis. About 90% of healthy adults who are infected with HBV will recover and be completely rid of the virus within six months.
Where is hepatitis B most common?
Hepati ti s B is endemic in China and other parts of Asia. Most people in the region become infected with HBV during childhood. In these regions, 8% to 10% of the adult populati on are is chronically infected. Liver cancer caused by HBV is among the fi rst three causes of death from cancer in men, and a major cause of cancer in women. In the Middle East and the Indian sub-conti nent, an esti mated 2% to 5% of the general populati on is chronically infected. Less than 1% of the populati on in western Europe and North American is chronically infected.
Transmission
Hepati ti s B virus is transmitt ed between people by contact with the blood or other body fl uids (i.e. semen and vaginal fl uid) of an infected person. Modes of transmission are the same for the human immunodefi ciency virus (HIV), but HBV is 50 to 100 ti mes more infecti ous. Unlike HIV, HBV can survive outside the body for at least 7 days. During that ti me, the virus can sti ll cause infecti on if it enters the body of a person who is not infected. The virus incubati on period is 90 days on average, but can vary from about 30 to 180 days. HBV may be detected 30 to 60 days aft er infecti on and persist for widely variable periods of ti me.
Common modes of transmission in developing countries are: perinatal (from mother to baby at birth);  early childhood infecti ons (in apparent infecti on through close interpersonal contact with  infected household contacts); unsafe injecti ons practi ces;  blood transfusions;  sexual contact.  HBV is a major infecti ous occupati onal hazard of health workers.
HBV is not spread by contaminated food or water, and cannot be spread casually in the workplace.
Treatment
There is no specifi c treatment for acute hepati ti s B. Care is aimed at maintaining comfort and adequate nutriti onal balance, including replacement of fl uids that are lost from vomiti ng and diarrhoea.
Chronic hepati ti s B can be treated with drugs, including interferon and anti -viral agents, which can help some pati ents. Treatment can cost thousands of dollars per year and is not available to most pati ents in developing countries.
Liver cancer is almost always fatal, and oft en develops in people at an age when they are most producti ve and have family responsibiliti es. In developing countries, most people with liver cancer die within months of diagnosis. In higher income countries, surgery and chemotherapy can prolong life for up to a few years in some pati ents.
Prevention
All infants should receive the hepati ti s B vaccine: this is the mainstay of hepati ti s B preventi on. The vaccine can be given as either three or four separate doses, as part of existi ng routi ne immunizati on schedules. In areas where mother-to-infant spread of HBV is common, the fi rst dose of vaccine should be given as soon as possible aft er birth (i.e. within 24 hours).
The complete vaccine series induces protecti ve anti body levels in more than 95% of infants, children and young adults. Aft er age 40, protecti on following the primary vaccinati on series drops below 90%. At 60 years old, protecti ve anti body levels are achieved in only 65 to 75% of those vaccinated. Protecti on lasts at least 30 years and should be lifelong.
All children and adolescents younger than 18 years and not previously vaccinated should receive the vaccine. People in high-risk groups should also be vaccinated, including:
persons with high-risk sexual behaviour;  partners and household contacts of HBV infected persons;  injecti ng drug users;  persons who frequently require blood or blood products;  recipients of solid organ transplantati on;  those at occupati onal risk of HBV infecti on, including health care workers; and internati onal  travelers to countries with high rates of HBV.
The vaccine has an outstanding record of safety and eff ecti veness. Since 1982, over one billion doses of hepati ti s B vaccine have been used worldwide. In many countries where 8% to 15% of children used to become chronically infected with HBV, vaccinati on has reduced the rate of chronic infecti on to less than 1% among immunized children.
As of December 2010, 177 countries vaccinate infants against hepati ti s B during nati onal immunizati on programmes. 87 Member States are reporti ng providing Hepati ti s B vaccine at birth.
